HIV and Vaccination: Guidelines, Safety, and Recommended Vaccines
People living with HIV (PLWH) can and should receive most routine vaccines. Vaccination is a critical component of preventive care because HIV increases susceptibility to certain infections and their complications.
General Principles
- Inactivated/killed vaccines are safe at any CD4 count.
- Live attenuated vaccines (MMR, varicella, yellow fever, intranasal influenza, oral typhoid) are generally contraindicated if CD4 < 200 cells/µL or if the patient is severely immunocompromised. They may be considered if CD4 ≥ 200 and viral load is suppressed.
- Vaccine response may be blunted with low CD4 counts; revaccination after immune reconstitution (on ART) is often recommended.
Routinely Recommended Vaccines for Adults with HIV
| Vaccine | Schedule / Notes |
|---|---|
| Hepatitis B | 3-dose series (0, 1, 6 mo); check anti-HBs titer post-vaccination; revaccinate if non-responder |
| Hepatitis A | 2-dose series; recommended for all PLWH |
| MMR (Measles, Mumps, Rubella) | Live vaccine; give if CD4 ≥ 200; 2 doses if no evidence of immunity |
| Varicella (Chickenpox) | Live vaccine; give if CD4 ≥ 200; 2 doses if no immunity |
| Tdap / Td | Tdap once, then Td/Tdap booster every 10 years |
| Influenza (inactivated) | Annual; avoid live intranasal (LAIV) |
| Pneumococcal | PCV20 alone, or PCV15 followed by PPSV23 ≥1 year later |
| HPV (Human Papillomavirus) | 3-dose series through age 26; shared decision-making for 27–45 |
| COVID-19 | Updated mRNA/protein vaccines per current CDC guidance; additional doses if immunocompromised |
| Herpes Zoster (Shingles) | Recombinant zoster vaccine (RZV/Shingrix) 2 doses – preferred (non-live); safe at any CD4 |
| Meningococcal (MenACWY, MenB) | Based on risk factors (asplenia, travel, outbreaks) |
Special Considerations
- Timing: Vaccinate early after HIV diagnosis, ideally after ART initiation and CD4 recovery.
- Monitoring: Check antibody titers for Hep B; consider pneumococcal titer if high risk.
- Travel Vaccines: Yellow fever (live) requires CD4 ≥ 200 and careful risk-benefit assessment; oral typhoid (live) avoided if CD4 < 200.
Consultation
Decisions should be made with an HIV specialist or infectious disease provider who can assess immune status, ART adherence, and individual risk factors.
HIV & AIDS - Related Articles
- The Discovery of AIDS: Origins and Early Cases
- HIV and Pregnancy: Transmission Risks and Prevention
- Early HIV Testing: Critical Benefits for Individual and Public Health
- Understanding Acute HIV Infection: Symptoms & Duration
- Foreskin Variation: Normal Anatomy, Not Race-Based
- AIDS and HIV: How Immune Destruction Leads to Opportunistic Diseases
- Origins of HIV: From Simian Viruses to Global Pandemic
